Inactive Instrument

Science 37 Holdings, Inc.

SNCE

US8086442071

Science 37 Holdings, Inc. Provides Revenue Guidance for Year Ending December 31, 2022

August 11, 2022 at 06:00 am EDT

Science 37 Holdings, Inc. provided revenue guidance for year ending December 31, 2022. The company expects revenue of $76 million to $86 million.

Latest news about Science 37 Holdings, Inc.

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance	May. 13	CI
Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial	May. 02	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index	Mar. 11	CI
Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from S&P TMI Index	Mar. 11	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
EMed, LLC completed the acquisition of Science 37 Holdings, Inc..	Mar. 10	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
North American Morning Briefing : Big Tech Weighs -2-	Jan. 31	DJ
Baird Downgrades Science 37 Holdings to Neutral From Outperform, Price Target is $5.75	Jan. 30	MT
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
Baird Adjusts Science 37 Holdings' Price Target to $5.75 From $15, Keeps Outperform Rating	Jan. 29	MT
Craig-Hallum Downgrades Science 37 Holdings to Hold From Buy	Jan. 29	MT
Science 37 to be Acquired by eMed for About $38 Million in Cash	Jan. 29	MT
EMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc..	Jan. 28	CI
Science 37 Holdings, Inc. Provides Revenue Guidance for the Full Year 2024	Nov. 07	CI
Transcript : Science 37 Holdings, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (SNCE) SCIENCE 37 Posts Q3 Revenue $14.9M, vs. Street Est of $14.8M	Nov. 07	MT
Science 37 Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023	Nov. 07	CI
Science 37 Holdings, Inc. Reports Impairment for the Third Quarter Ended September 30, 2023	Nov. 07	CI
Transcript : Science 37 Holdings, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Earnings Flash (SNCE) SCIENCE 37 Reports Q2 Revenue $15.4M, vs. Street Est of $12.6M	23-08-08	MT
Science 37 Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Science 37 Holdings, Inc. Revises Revenue Guidance for the Full Year 2023	23-08-08	CI

Chart Science 37 Holdings, Inc.

Duration

Period

More charts

Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. It also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. It uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.

Sector

Software

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Software

	1st Jan change	Capi.
MICROSOFT CORPORATION	+12.51%	3,144B
SYNOPSYS INC.	+12.68%	88.51B
DASSAULT SYSTÈMES SE	-13.71%	54.56B
PALANTIR TECHNOLOGIES INC.	+26.21%	48.26B
ATLASSIAN CORPORATION	-22.56%	47.95B
THE TRADE DESK, INC.	+25.42%	44.14B
SEA LIMITED	+69.48%	39.42B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-8.00%	25.26B
SAMSARA INC.	+26.00%	23.15B

Other Software